Beginning next year, the government will charge health insurance plans a new fee for research to find out which drugs, medical procedures, tests and treatments work best. But what will Americans do with the answers?
The goal of the research, part of a little-known provision of President Obama’s health care law, is to answer such basic questions as whether a new prescription drug advertised on TV really works better than an old generic costing much less.
But in the politically charged environment surrounding health care, the idea of medical effectiveness research is eyed with suspicion. The insurance fee could be branded a tax and drawn into the vortex of election-year politics.
The Patient-Centered Outcomes Research Institute — a quasi-governmental agency created by Congress to carry out the research — has yet to commission a single head-to-head comparison, although its director is anxious to begin.
The government is already providing the institute with some funding: The $1-per-person insurance fee goes into effect in 2012. But the Treasury Department says it’s not likely to be collected for another year, though insurers would still owe the money. The fee doubles to $2 per covered person in its second year and thereafter rises with inflation. The IRS is expected to issue guidance to insurers within the next six months.
“The more concerning thing is not the institute itself, but how the findings will be used in other areas,” said Kathryn Nix, a policy analyst for the conservative Heritage Foundation think tank. “Will they be used to make coverage determinations?”
The institute’s director, Dr. Joe Selby, said patients and doctors will make the decisions, not his organization.
“We are not a policy-making body; our role is to make the evidence available,” said Dr. Selby, a primary-care physician and medical researcher.
But insurance industry representatives say they expect to use the research and work with employers to fine-tune workplace health plans. Employees and family members could be steered to hospitals and doctors who follow the most effective treatment methods. Patients going elsewhere could face higher copayments, similar to added charges they now pay for “nonpreferred” drugs on their insurance plans.
Major insurers already are doing their own effectiveness research, but it lacks the credibility of government-sponsored studies.
Not long ago, so-called “comparative effectiveness” research enjoyed support from lawmakers in both parties.
The 2009 economic stimulus bill included $1.1 billion for medical-effectiveness research, mainly through the National Institutes of Health. It was not considered particularly controversial. But things changed during the congressional health care debate, after former GOP vice presidential candidate Sarah Palin made the claim, now widely debunked, that Obama and the Democrats were setting up “death panels” to ration care.
As a result, lawmakers hedged the new institute with caveats. It was set up as an independent nonprofit organization, with a .org. Internet address instead of .gov. The government cannot dictate Dr. Selby’s research agenda. And there are limitations on how the Department of Health and Human Services can use the research findings in decisions that affect Medicare and Medicaid.
Copyright © 2022 The Washington Times, LLC.